ONCOassist

07/01/2026

🚨New Oncology Update!

🔔 ZIIHERA® (zanidatamab) + TEVIMBRA® (tislelizumab) + chemotherapy showed compelling survival and disease control versus the current standard in first-line HER2+ advanced gastroesophageal adenocarcinoma (GEA), regardless of PD-L1 status.

🌏 High GEA burden in Asia highlights broad patient impact; results to be shared as a late-breaking oral presentation at ASCO GI 2026.

🔗 Read more: bit.ly/ONCOnews07J-05

07/01/2026

“Quality of life matters in cancer care.”

Dr .kalantri explains why quality of life must guide cancer care decisions.

🔗Watch the full episode in link in bio



[Oncology Spotlight, Podcast, Shreyas Kalantri, HemOnc Fellows Network]

07/01/2026

🚨Latest Approval Alert!

✅ First in world approval: China grants approval for sonrotoclax, a next-generation BCL2 inhibitor, for adults with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL).

🧬 Approval based on two studies presented at ASH 2025, highlighting sonrotoclax’s potential as a foundational therapy across B-cell malignancies.

🔗 Read more: bit.ly/ONCOnews07J-04

07/01/2026

🔔 Phase III COMMIT Trial Update!

✅ Targeted therapy + immunotherapy improved outcomes vs immunotherapy alone in first-line dMMR/MSI-H metastatic colorectal cancer (mCRC).

📊 Key outcome: Median progression-free survival (PFS) 30 months vs 4.3 months, with the combination reducing the risk of progression by >50%.

🔗 Read more: bit.ly/ONCOnews07J-03

07/01/2026

📘 ASCO–Ontario Health Living Guideline:

➡️ Daratumumab may be offered for patients with high risk smoldering multiple myeloma.

📌 Quadruplet anti-CD38 + VRd regimens are recommended for both transplant-eligible and suitable transplant-ineligible patients.

🔗 Read more: bit.ly/ONCOnews07J-02

07/01/2026

🚨Latest National Medical Products Administration (NMPA) Approval!

✅ Zai Lab’s AUGTYRO™ (repotrectinib) approved in China for adult patients with neurotrophic tyrosine receptor kinase (NTRK) fusion positive solid tumors.

🧬 Indicated for locally advanced or metastatic disease, or when surgery may cause morbidity, in patients who have progressed on prior therapies or lack satisfactory alternatives.

🔗 Read more: bit.ly/ONCOnews07J-01

06/01/2026

🚨ASCO Gastrointestinal Cancers Symposium 2026!

📊 GLP-1 receptor agonists were linked to a 26% relative reduction in CRC incidence vs aspirin, with semaglutide showing a significant protective benefit.

⚠️ Other GLP-1 RAs were not significant (smaller samples), and results were limited by a less diverse cohort.

🔗 Read more: bit.ly/ONCOnews06J-06

06/01/2026

🚨ASCO Gastrointestinal Cancers Symposium 2026!

🧭 The Colorectal Cancer Alliance’s Clinical Navigation Program improved access to biomarker testing, clinical trial education, and second opinions for patients navigating complex CRC care.

🌍 The program effectively reached younger patients, those with advanced disease, with plans to scale and further evaluate outcomes.

🔗 Read more: bit.ly/ONCOnews06J-05

06/01/2026

🎙️New Episode | Oncology Spotlight

"How patients live matters just as much as how long they live."

Dr. Shreyas Kalantri, Chief Fellow in Hematology & Oncology at the University of Louisville, shares powerful insights on why quality of life must contextualize survival, the realities of immunotherapy disparities, and how AI can reshape oncology workflows.
A must-watch episode for oncologists, trainees, and healthcare leaders shaping the future of cancer care.

🎧 Watch the full episode: https://youtu.be/-bH1jc3Nzqo

Download the ONCOassist app:
📥 iOS: https://apple.co/4iuMxfS
📥 Android: https://bit.ly/oncoassistonandroid
📥Webapp: https://bit.ly/ONCOassistOnWeb

🌐 Explore ONCOassist – clinical tools for oncology professionals: https://oncoassist.com/

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, treatment protocols, and calculators! 🔬In this episode, Dr. Shreyas Kal...

06/01/2026

🚨ASCO Gastrointestinal Cancers Symposium 2026!

🧬 Early-onset dMMR/MSI-H CRC shows distinct clinical and molecular features vs late-onset disease, including higher mutation rates (KRAS, APC, PIK3CA, PTEN, MLH1, MSH2) and differing demographic patterns.

📈 Early-onset CRC is rising globally, now accounting for ~10% of cases and often presenting as advanced, left-sided disease.

🔗 Read more: bit.ly/ONCOnews06J-04

06/01/2026

🚨ASCO Gastrointestinal Cancers Symposium 2026!

➡️ New studies show local HER2 testing largely aligns with central lab results in gastric cancer and GEJ adenocarcinoma, supporting real-world decision-making.

🔄 HER2 status may change over time in advanced upper GI cancers, with loss of overexpression frequently observed, highlighting the potential value of repeat testing in selected patients.

🔗 Read more: bit.ly/ONCOnews06J-03

06/01/2026

🚨 ASCO Gastrointestinal Cancers Symposium 2026!

🧬 Phase 2 trial Update: Durvalumab + olaparib demonstrated durable antitumor activity in DNA damage repair (DDR)-mutated metastatic pancreatic cancer after prior platinum therapy.

🔬Previous research has shown that Metastatic Prostate Cancer (mPC) with DDR alterations such as those to BRCA1, BRCA2, and PALB2 is sensitive to platinum-based chemotherapy as well as PARP inhibition.

🔗 Read more: bit.ly/ONCOnews06J-02